Glucagon-Like Peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor

Endocrinology

Volumn 151, Issue 4, 2010, Pages 1520-1531

  Ban, Kiwon ^a,c   Kim, Kyoung Han ^a,c   Cho, Chan Kyung ^a   Sauvé, Meghan ^b,c   Diamandis, Eleftherios P ^a   Backx, Peter H ^a,c   Drucker, Daniel J ^a,b,c   Husain, Mansoor ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLIC AMP; EXENDIN (9 39); EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9 36] AMIDE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CONVALESCENCE; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPERFUSION;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; HEART; MALE; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; MYOCARDIUM; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, GLUCAGON; RECOVERY OF FUNCTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TIME FACTORS; VENOMS;

EID: 77950267745     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-1197     Document Type: Article

References (52)

1. Elrick H, Stimmler L, Hlad Jr CJ, Arai Y 1964 Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1082
2. McIntyre N, Holdsworth CD, Turner DS 1965 Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 25:1317-1324
3. Baggio LL, Drucker DJ 2007 Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157
4. Kieffer TJ, McIntosh CH, Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagonlike peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
5. Mentlein R, Gallwitz B, Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
6. Vilsbøll T, Agersø H, Krarup T, Holst JJ 2003 Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224
7. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagonlike peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
8. Knudsen LB, Pridal L 1996 Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-435
9. Deacon CF, Plamboeck A, Møller S, Holst JJ 2002 GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol 282:E873-E879
10. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA 2003 Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-1779
11. Zander M, Madsbad S, Deacon CF, Holst JJ 2006 The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 49:369-374
12. Nikolaidis LA, Elahi D, Shen YT, Shannon RP 2005 Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2401-H2408
13. Sonne DP, Engstrøm T, Treiman M 2008 Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemiareperfusion injury in rat heart. Regul Pept 146:243-249
14. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M2008 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350
15. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B 2004 Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654-662
16. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T 2009 Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Peptides 157:8-13
17. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
18. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 2:1254-1258
19. Ban K, Cooper AJ, Samuel S, Bhatti A, Patel M, Izumo S, Penninger JM, Backx PH, Oudit GY, Tsushima RG 2008 Phosphatidylinositol 3-kinase γ is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ Res 103:643-653
20. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ 2009 GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983
21. Kim KH, Oudit GY, Backx PH 2008 Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 324:160-169
22. Costantini DL, Arruda EP, Agarwal P, Kim KH, Zhu Y, Zhu W, Lebel M, Cheng CW, Park CY, Pierce SA, Guerchicoff A, Pollevick GD, Chan TY, Kabir MG, Cheng SH, Husain M, Antzelevitch C, Srivastava D, Gross GJ, Hui CC, Backx PH, Bruneau BG 2005 The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 123:347-358
23. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K 2000 Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101:660-667
24. Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL 2002 Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 105:1497-1502
25. Morisco C, Marrone C, Trimarco V, Crispo S, Monti MG, Sadoshima J, Trimarco B 2007 Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc Res 76:453-464
26. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL 2007 Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115:1408-1416
27. Oshima Y, Ouchi N, Sato K, Izumiya Y, Pimentel DR, Walsh K 2008 Follistatin-like 1 is an Akt-regulated cardioprotective factor that is secreted by the heart. Circulation 117:3099-3108
28. Ohori K, Miura T, Tanno M, Miki T, Sato T, Ishikawa S, Horio Y, Shimamoto K 2008 Ser9 phosphorylation of mitochondrial GSK-3β is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 295:H2079-H2086
29. Eguchi M, Liu Y, Shin EJ, Sweeney G 2008 Leptin protects H9c2 rat cardiomyocytes from H2O2-induced apoptosis. FEBS J 275: 3136-3144
30. Han H, Long H, Wang H, Wang J, Zhang Y, Wang Z 2004 Progressive apoptotic cell death triggered by transient oxidative insult in H9c2 rat ventricular cells: a novel pattern of apoptosis and the mechanisms. Am J Physiol Heart Circ Physiol 286:H2169-H2182
31. Murata H, Ihara Y, Nakamura H, Yodoi J, Sumikawa K, Kondo T 2003 Glutaredoxin exerts an antiapoptotic effect by regulating the redox state of Akt. J Biol Chem 278:50226-50233
32. Yasuoka C, Ihara Y, Ikeda S, Miyahara Y, Kondo T, Kohno S 2004 Antiapoptotic activity of Akt is down-regulated by Ca2+ in myocardiac H9c2 cells: evidence of Ca2+-dependent regulation of protein phosphatase 2Ac. J Biol Chem 279:51182-51192
33. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, Pinna A, Gaspa L, Regoli D, Cayla C, Pesquero JB, Bader M, Madeddu P 2002 Targeting kinin B1 receptor for therapeutic neovascularization. Circulation 105:360-366
34. Esumi K, Nishida M, Shaw D, Smith TW, Marsh JD 1991 NADH measurements in adult rat myocytes during simulated ischemia. Am J Physiol Heart Circ Physiol 260:H1743-H1752
35. Ma H, Zhang HF, Yu L, Zhang QJ, Li J, Huo JH, Li X, Guo WY, Wang HC, Gao F 2006 Vasculoprotective effect of insulin in the ischemic/reperfused canine heart: role of Akt-stimulated NO production. Cardiovasc Res 69:57-65
36. Bergmann MW, Rechner C, Freund C, Baurand A, El Jamali A, Dietz R 2004 Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3β and transcription factor β-catenin. J Mol Cell Cardiol 37:681-690
37. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, Falck JR, Patel PK, Jacobs ER, Medhora M 2008 Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 294:H724-H735
38. Germack R, Dickenson JM 2005 Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39:429-442
39. Gomez LA, Alekseev AE, Aleksandrova LA, Brady PA, Terzic A 1997 Use of the MTT assay in adult ventricular cardiomyocytes to assess viability: effects of adenosine and potassium on cellular survival. J Mol Cell Cardiol 29:1255-1266
40. Thuerauf DJ, Marcinko M, Gude N, Rubio M, Sussman MA, Glembotski CC 2006 Activation of the unfolded protein response in infarcted mouse heart and hypoxic cultured cardiac myocytes. Circ Res 99:275-282
41. Woo AY, Cheng CH, Waye MM 2005 Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res 65:244-253
42. Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, Diamandis EP 2008 "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 7:640-647
43. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM 2005 Glucagon-like peptide-1 (GLP-1) can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146-151
44. Das S, Tosaki A, Bagchi D, Maulik N, Das DK 2005 Resveratrolmediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther 314:762-769
45. Marais E, Genade S, Lochner A 2008 CREB activation and ischaemic preconditioning. Cardiovasc Drugs Ther 22:3-17
46. Markou T, Hadzopoulou-Cladaras M, Lazou A 2004 Phenylephrine induces activation of CREB in adult rat cardiac myocytes through MSK1 and PKA signaling pathways. J Mol Cell Cardiol 37:1001-1011
47. Matus M, Lewin G, Stümpel F, Buchwalow IB, Schneider MD, Schütz G, Schmitz W, Müller FU 2007 Cardiomyocyte-specific inactivation of transcription factor CREB in mice. FASEB J 21:1884-1892
48. Mehrhof FB, Müller FU, Bergmann MW, Li P, Wang Y, Schmitz W, Dietz R, von Harsdorf R 2001 In cardiomyocyte hypoxia, insulin-like growthfactor-I-induced antiapoptotic signaling requires phosphatidylinositol-3- OH-kinase-dependent and mitogen-activated protein kinase-dependent activation of the transcription factor cAMP response element-binding protein. Circulation 104:2088-2094
49. Nagy N, Shiroto K, Malik G, Huang CK, Gaestel M, Abdellatif M, Tosaki A, Maulik N, Das DK 2007 Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol 42:981-990
50. Gault VA,O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR 2003 Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 46:222-230
51. Wheeler MB, Gelling RW, McIntosh CH, Georgiou J, Brown JC, Pederson RA 1995 Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 136:4629-4639
52. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ 2008 GLP-1 and related peptides cause concentrationdependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 478:136-142